Publication date: November 2026 Source: Ophthalmology, Volume 133, Issue 11 Author(s): Jennifer Chan, Michael X. Repka, George A. Williams, Daniel Vail, Flora Lum, Tedi Begaj, Scott Friedman, Ravi Parikh
Access to Intravitreal Anti-VEGF Drugs in Persons with Medicare Advantage Compared with Medicare Fee-For-Service Coverage. // Ophthalmology. – URL: https://www.sciencedirect.com/science/article/pii/S0161642026004537?dgcid=rss_sd_all
Access to Intravitreal Anti-VEGF Drugs in Persons with Medicare Advantage Compared with Medicare Fee-For-Service Coverage. Ophthalmology. https://www.sciencedirect.com/science/article/pii/S0161642026004537?dgcid=rss_sd_all
“Access to Intravitreal Anti-VEGF Drugs in Persons with Medicare Advantage Compared with Medicare Fee-For-Service Coverage.” Ophthalmology.
@article{article90354,
title = {Access to Intravitreal Anti-VEGF Drugs in Persons with Medicare Advantage Compared with Medicare Fee-For-Service Coverage},
journal = {Ophthalmology},
url = {https://www.sciencedirect.com/science/article/pii/S0161642026004537?dgcid=rss_sd_all}
}
Abstract Purpose To compare the efficacy of intravitreal dexamethasone (DEX) implant‐based regimen versus ranibizumab‐based regimen for managing retinal exudation and complications in stage 3 Coats' disease. Methods Thirty‐seven eyes...
Abstract Foundation models are rapidly emerging as a major development in ophthalmic artificial intelligence, largely because they can achieve strong downstream performance with fewer labelled images than conventional supervised models,...
Abstract Purpose To evaluate intraretinal fluid (IRF) volume dynamics after switching from aflibercept 2 mg to faricimab in eyes with diabetic macular oedema (DME), stratified by prior response to aflibercept. Methods This retrospective...